At the International Neuromodulation Society 12th World Congress, Bioness, Inc. announced the commercial availability of StimRouter, an implantable neuromodulation device to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy (e.g., medications). StimRouter received clearance from the United States Food and Drug Administration (FDA) in February and is the only implantable neuromodulation device indicated to treat chronic pain of peripheral nerve origin.
Bioness President and CEO Todd Cushman commented, “The commercial launch of StimRouter for peripheral pain positions Bioness to strategically build on the success of our neuromodulation portfolio. In addition to pain applications, we started a pilot study for overactive bladder in February and we anticipate expanding to other commercial markets in the future.”
With an estimated 50 million people suffering from chronic pain, contributing an additional $150 billion in annual costs to the U.S. healthcare system, there’s never been a greater need for innovative pain management options. As a minimally invasive device designed to reduce pain by specifically targeting the affected peripheral nerve, StimRouter is a cost-effective alternative to injections, ongoing medication regiments and complex surgeries.
About StimRouter Neuromodulation System
StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. Each system is programmed at the direction of the physician to meet patient requirements.